Total Payments
$1,576
2024 Payments
$364.57
Companies
19
Transactions
82
Medicare Patients
3,410
Medicare Billing
$610,048
Payment Breakdown by Category
Food & Beverage$1,377 (87.4%)
Education$199.26 (12.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,377 | 73 | 87.4% |
| Education | $199.26 | 9 | 12.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $276.08 | 12 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $256.16 | 15 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $146.35 | 3 | $0 (2024) |
| Travere Therapeutics, Inc. | $138.59 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $138.34 | 8 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $134.43 | 7 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $107.22 | 7 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $84.54 | 4 | $0 (2024) |
| Vifor Pharma, Inc. | $72.42 | 3 | $0 (2023) |
| Genentech USA, Inc. | $37.75 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $364.57 | 19 | Travere Therapeutics, Inc. ($94.57) |
| 2023 | $200.72 | 10 | Fresenius USA Marketing, Inc. ($61.38) |
| 2022 | $71.44 | 5 | Fresenius USA Marketing, Inc. ($19.67) |
| 2021 | $169.08 | 5 | Mallinckrodt Hospital Products Inc. ($119.68) |
| 2020 | $110.85 | 6 | Amgen Inc. ($35.25) |
| 2019 | $172.21 | 9 | Amgen Inc. ($72.83) |
| 2018 | $301.66 | 17 | Amgen Inc. ($79.66) |
| 2017 | $185.61 | 11 | Keryx Biopharmaceuticals, Inc. ($79.05) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Nephrology | ||||||
| 09/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Immunology | ||||||
| 07/31/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: NEPHROLOGY | ||||||
| 07/30/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 07/15/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 06/19/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Phosphate binder for ESRD | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/30/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $22.70 | General |
| 04/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.56 | General |
| 04/03/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: NEPHROLOGY | ||||||
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/16/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Inflammation | ||||||
| 02/02/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.83 | General |
| 02/02/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 01/29/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 12/05/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: DIABETES | ||||||
| 12/01/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $31.22 | General |
| Category: Hyperkalemia | ||||||
| 11/21/2023 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $1.10 | General |
| Category: Kidney Stones | ||||||
| 09/26/2023 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/19/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Nephrology | ||||||
| 08/30/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $17.91 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 740 | 1,238 | $279,060 | $109,641 |
| 2022 | 15 | 873 | 1,689 | $384,232 | $156,204 |
| 2021 | 16 | 878 | 1,942 | $421,536 | $172,636 |
| 2020 | 16 | 919 | 2,046 | $468,845 | $171,567 |
Total Patients
3,410
Total Services
6,915
Medicare Billing
$610,048
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 233 | 385 | $84,700 | $30,844 | 36.4% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 19 | 64 | $35,200 | $15,822 | 44.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 260 | $33,540 | $15,039 | 44.8% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 11 | 48 | $23,760 | $9,382 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 111 | $14,208 | $6,663 | 46.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 15 | 32 | $15,840 | $6,267 | 39.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 47 | 108 | $21,384 | $5,632 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $14,308 | $5,369 | 37.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 45 | 48 | $11,712 | $4,442 | 37.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 33 | $6,138 | $2,786 | 45.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 21 | $5,334 | $2,642 | 49.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $5,445 | $2,101 | 38.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $6,120 | $2,066 | 33.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 14 | $1,008 | $514.22 | 51.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 33 | 33 | $363.00 | $72.60 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 221 | 351 | $77,220 | $30,107 | 39.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 18 | 94 | $51,700 | $24,960 | 48.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 167 | 452 | $57,876 | $23,848 | 41.2% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 11 | 80 | $39,600 | $17,459 | 44.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 62 | 224 | $43,245 | $12,136 | 28.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 15 | 42 | $20,790 | $9,384 | 45.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 60 | 61 | $21,960 | $9,041 | 41.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 95 | $17,670 | $7,289 | 41.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 53 | 59 | $14,396 | $5,940 | 41.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $13,794 | $5,145 | 37.3% |
About Dr. Sathiyendran Poobalasingham, MD
Dr. Sathiyendran Poobalasingham, MD is a Nephrology healthcare provider based in Kingsport, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639210222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sathiyendran Poobalasingham, MD has received a total of $1,576 in payments from pharmaceutical and medical device companies, with $364.57 received in 2024. These payments were reported across 82 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($1,377).
As a Medicare-enrolled provider, Poobalasingham has provided services to 3,410 Medicare beneficiaries, totaling 6,915 services with total Medicare billing of $610,048. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Kingsport, TN
- Active Since 02/08/2007
- Last Updated 11/21/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639210222
Products in Payments
- Velphoro (Drug) $238.65
- ACTHAR (Biological) $182.78
- Auryxia (Drug) $170.84
- Parsabiv (Biological) $152.49
- Veltassa (Drug) $90.15
- LOKELMA (Drug) $62.62
- FARXIGA (Drug) $55.16
- SAMSCA (Drug) $54.03
- JYNARQUE (Drug) $53.19
- Sensipar (Drug) $43.42
- Rituxan (Biological) $37.75
- Parsabiv (Drug) $35.25
- TAVNEOS (Drug) $25.13
- Vafseo (Drug) $24.61
- TARPEYO (Drug) $24.54
- AURYXIA (Drug) $23.52
- IBSRELA (Drug) $21.91
- KRYSTEXXA (Biological) $19.79
- LUPKYNIS (Drug) $19.69
- NORTHERA (Drug) $19.40
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.